Peptide/Protein Ingredients TRIZ Cases

Cryopreserved chorionic membrane preserves viable therapeutic cells while reducing immunogenicity for wound, burn, and tissue repair.

Peptides derived from the B-Raf dimer interface inhibit mutant RAF dimerization, reducing ERK signaling and tumor growth in resistant melanoma.

A composite diffusion-resistance layer stabilizes glucose sensor permeability, reducing drift and interference during continuous measurement.

Multiple gene edits and tolerogenic factor insertions reduce MHC-driven rejection and improve post-engraftment survival of donor cells.

Hyaluronidase lowers tissue resistance to enable high-volume subcutaneous dosing with less pain, back leakage, swelling, and delivery force.

Biased IL-2 conjugates favor IL-2Rβγ signaling to boost effector T cells and NK cells while limiting toxicity and Treg-driven suppression.

Stapled polypeptides target the LRRK2 RocCOR region to reduce kinase activity without localization-driven kidney, lung, or transport toxicity.

Daily anakinra dosing helps control IL-1 driven inflammation in PACS, improving lung and cardiac function while easing fatigue and breathlessness.

A hydrophobic core and hydrophilic-hydrophobic membrane regulate slow diffusion of biologic macromolecules for steadier implant release.

A phosphate-buffered, sodium chloride hemopexin liquid maintains stability at 50 mg/mL+ for heme binding and reduced oxidative tissue damage.

Modified SBT-20 analogs improve mitochondrial targeting, selectivity, and metabolic properties for ischemia-reperfusion injury treatment.

Digestive enzymes are used to cleave the SARS-CoV-2 spike protein, offering prophylactic and therapeutic support beyond vaccines.

Modified anti-miR-17 oligonucleotides slow kidney cyst growth and preserve function in polycystic kidney disease.

A thickened intranasal oxytocin formulation targets the upper nasal cavity to relieve visual snow syndrome with fewer doses and adverse events.

An RAR agonist composition suppresses renal cyst enlargement without the fluid-loss burden of tolvaptan, improving treatment potential.

Dual inhibition targets PI3Kδ-S-driven resistance by reversing aberrant splicing and suppressing AKT/mTOR signaling in solid tumors.

Engineered NY-ESO-1 TCRs use tailored CDRs and disulfide bonds to improve T-cell persistence, specificity, and anti-tumor activity.

Modified Spirulina expressing methanolysins suppresses rumen methanogens to cut enteric methane without the toxicity and scaling limits of inhibitors.

A synthetic antifungal peptide expressed in maize kernels suppresses Aspergillus flavus growth and sharply lowers aflatoxin contamination.

A buffered G-CSF dimer formulation uses stabilizers, tonicity agents, and surfactant to limit aggregation, control osmolality, and improve injection tolerability.

By fusing NK ligand recognition with CD3ζ signaling, engineered T cells bypass rare tumor-specific T cell isolation and kill MHC-I-deficient tumors.

C-terminal Michael-acceptor peptidomimetics selectively and irreversibly inhibit FXIIIa while avoiding thrombin and fibrin interference.

A polymer-surfactant solid dosage form delivers APIs through buccal and sublingual tissues to avoid GI side effects and improve compliance.

Lipid-linked chemerin analog peptides modulate CMKLR1 to treat refractory neuropathic pain, ocular pain, and inflammatory conditions.

Surface-tethered and secreted sialidase equips CAR T cells to remodel solid tumor glycans, improving recognition, activation, and cytotoxicity.

Engineered glutamine-linked IL-2 PEG conjugates extend serum exposure and reduce IL-2Rα-driven toxicity while preserving anti-tumor immune activation.

Enucleated cytoplasts retain therapeutic delivery while avoiding uncontrolled proliferation, mutation risk, and host genetic transfer.

Small-molecule [F18] PSMA imaging agents use click chemistry and rapid clearance to raise tumor-to-muscle ratios in prostate cancer PET.

Oral intestinal alkaline phosphatase dephosphorylates inflammatory gut triggers to reduce CPI-related diarrhea and colitis without blunting immunotherapy.

A recombinant adenovirus delivers a GLP-1 receptor agonist to boost CD8+ T-cell killing while suppressing tumor-promoting inflammation.

Oral biopolymer hydrogels bind PFAS and synthetic food dyes in the digestive tract, enabling excretion without systemic absorption.

Layered birth tissue implants combine amniotic, placental, or umbilical tissues with added agents to improve healing in a more usable repair format.

A dual ICOS and PD-L1 antibody boosts T cell activation and anti-tumor response while reducing the complexity of multi-drug immunotherapy.

Steric masking and a tumor-cleavable linker keep cytokines inactive in circulation, then restore activity at tumor sites to limit systemic toxicity.

Peptide compounds tuned for skin penetration overcome the stratum corneum barrier and deliver local anti-cancer activity in skin tumors.

Combining p53 and MDA-7 gene delivery with CD122/CD132 agonists helps overcome tumor resistance and drive apoptosis and regression.

Uniform biodegradable leuprolide microparticles control release for over a month while limiting initial burst and injection pain.

A fibrin-derived Bβ15-42 peptide stabilizes VE-cadherin-mediated endothelial barriers to reduce inflammation and capillary leakage in viral endothelitis.

Specific shrimp allergen epitopes improve IgE binding detection, enabling more precise diagnosis and better assessment of cross-reactivity.

Macrophage-derived extracellular vesicles improve erythroid precursor differentiation and maturation, supporting more efficient in vitro red blood cell production.

Enteric-coated IL-23R peptide inhibitors enable oral delivery to the lower GI tract while protecting peptide stability and reducing intestinal inflammation.

Targeted meganucleases cleave the TTR gene and use NHEJ repair to stably lower transthyretin levels for amyloidosis treatment.

A mild Tween-20 decellularization route removes α-Gal and other immunogens while preserving ECM structure and bioactivity for tissue repair.

Novel IL-23R-binding peptides improve oral delivery while blocking IL-23 signaling to treat intestinal inflammation and related diseases.

Targeted HD2 peptide modifications disrupt BCL9/β-catenin binding, downregulate Wnt signaling, and suppress neoplastic cell growth.

Ligand-based CAR constructs target hematopoietic stem and cancer stem cells to improve depletion and strengthen cancer remission outcomes.

PAK4 activation boosts CRTC1 and CREB-driven protective factors to suppress neuronal death beyond symptom-only brain degeneration treatment.

Membrane-bound IL-18 boosts CAR and TCR immune cell proliferation, persistence, and cytokine output in suppressive tumor microenvironments.

pHLIP-radionuclide complexes target acidic tumor tissue to improve uptake and retention while limiting non-tumor accumulation in PET/SPECT imaging.

Time-ordered recombinant L-asparaginase dosing maintains serum activity while reducing hypersensitivity and aggregation in cancer treatment.